Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Xencor Inc chart...

About the Company

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product

CEO

Bassil Dahiyat

Exchange

NASDAQ

Website

http://www.xencor.com/

$421M

Total Revenue

301

Employees

$1B

Market Capitalization

-11.41

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $XNCR News

Death in Cancer Drug Trial Hinders Xencor’s Shares

7d ago, source: Los Angeles Business Journal

After reporting its fourth-quarter and full-year financials, Xencor Inc. sustained a steep drop in its share price.

Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)

11d ago, source:

Bassil Dahiyat, President & CEO of Xencor Inc (NASDAQ:XNCR), sold 12,528 shares of the company on March 5, 2024, according to ...

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

20d ago, source: Stockhouse

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the ...

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

28d ago, source: Stockhouse

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will ...

Xencor, Inc. (XNCR) Interactive Stock Chart - Yahoo Finance

28d ago, source: Yahoo Finance

PASADENA, Calif., February 20, 2024--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and ...

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

20d ago, source: Seeking Alpha

Good afternoon, and thank you for standing by. Welcome to Xencor's Fourth Quarter and Year End 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers ...

Xencor: Q4 Earnings Snapshot

21d ago, source: Houston Chronicle

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Tuesday reported a loss of $19.1 million in its fourth quarter. The Pasadena, California-based company said it had a loss ...

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

27d ago, source: Business Wire

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...